Marshall Edwards elects of William Rueckert to board

Thursday, April 14, 2011 12:01 PM

Marshall Edwards, an oncology company focused on the clinical development of therapeutics targeting cancer metabolism, has elected William D. Rueckert to its board of directors.

Rueckert's experience covers industries including healthcare, financial services and natural resources. He is the managing member of Oyster Management, an investment fund specializing in community banks. From 1991 to 2006 he was president and director of Rosow & Company. Rueckert previously served as a director of Marshall Edwards from March 2007 until March 2009 and soon after was appointed as a director of Novogen. He is also a member of the board of directors of Chelsea Therapeutics International.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs